Services
Discovery Sciences
Clinical success doesn't begin in therapeutic development. It begins in discovery.
The decisions that shape clinical outcomes are often made long before a protocol is written, a patient is enrolled or a trial begins. They are made when a hypothesis is created, targets are selected and biological mechanisms are prioritized for efficacy and safety considerations.
At IQVIA Laboratories Discovery Sciences, we believe drug discovery begins with rational possibility and ends with success for the patient.
Our Drug Discovery Services
We challenge the orthodoxy of drug development, which separates discovery and the clinic. Our clinic-first approach combines drug-hunter expertise, human-centric biology, innovation, advanced technologies and AI-assisted insights to guide better decisions earlier.
Design and Developability
We utilize our 20 years of expertise and a vast repository of preclinical and clinical data to optimize candidate design and progression.
-
Small molecules, antisense oligonucleotides (ASOs) and RNA therapeutics
-
Antibody Discovery through Specifica
-
AI-assisted design and optimization
-
High-quality predictive models based on vast datasets
-
Extensive capabilities from hit ID to preclinical candidate
-
Deep ADME/PK expertise
-
Structural biology and biophysics services
Disease Biology
Our therapeutic expertise enables us to quickly assess the effectiveness of drug action or target modulation in the right disease context.
-
Target validation and efficacy in advanced human-relevant cell models
-
Target engagement assessment
- Pharmacology methods
-
Immunology models (including In Vitro Immunology)
-
Infectious disease models
-
Biomarker discovery/validation
-
Translational technologies (in vivo imaging)
Human Safety NAMs
Our new approach methodologies (NAMs) are designed to deliver scalable, reproducible results with increased human relevance. Our experts can recommend where NAMs can be effectively applied, reducing reliance on traditional animal models while maintaining scientific rigor.
-
Fit-for-purpose, context-relevant assays at scale
-
NAMs across discovery, preclinical and early clinical development
-
Advanced cell-based and in silico models for human predictivity
-
IND-enabling on-target and off-organ toxicity panels for biologics
Transforming the probability of therapeutic success.
By integrating patient need, disease biology, broad modality options clinical translation and predictive insights from the start, we help identify the right therapy for the right indication aligning with patient selection, advancing candidates with greater confidence and a clearer path to clinical success.
Through clinically relevant science and experienced leadership, we help organizations challenge their assumptions, reduce risk and focus resources where they can have the greatest impact.
Tracking record of supporting clients in generating
>100
preclinical candidates delivered since 2000
54
Candidates reaching Phase I
36
Candidates reaching Phase II (POC)
4
Drugs approved and marketed by our clients
500+
patients
~500
publications
900+
Scientific experts delivering cutting-edge scientific and regulatory support.
Because drug discovery is not simply about finding what works in the lab.
It is about identifying what has the greatest potential to succeed for patients, utilizing data and known risk identifiers to advance programs with unprecedented speed and efficiency.
91%
Hit ID success rate
83%
Lead optimization success rate
84%
Hit-to-lead success rate
91%
Hit ID success rate
83%
Lead optimization success rate
84%
Hit-to-lead success rate
Browse Drug Discovery Services
Explore our comprehensive therapeutic area expertise across multiple disease areas.
Browse Drug Discovery Services
Large Molecule Immunology Rare Disease IND-Enabling Safety Early De-riskingRelated Services
Protein Sciences
Learn more
Antibody Libraries
Learn more
In Vitro Immunology
Learn more
Additional Specialty Testing Services
Learn more
